当前位置： SCI文献检索 > Open Forum Infectious Diseases期刊下所有文献 > Antimicrobial Resistance Surveillance and New Drug Development.

Antimicrobial Resistance Surveillance and New Drug Development.

Abstract：

:Surveillance represents an important informational tool for planning actions to monitor emerging antimicrobial resistance. Antimicrobial resistance surveillance (ARS) programs may have many different designs and can be grouped in 2 major categories based on their main objectives: (1) public health ARS programs and (2) industry-sponsored/product-oriented ARS programs. In general, public health ARS programs predominantly focus on health care and infection control, whereas industry ARS programs focus on an investigational or recently approved molecule(s). We reviewed the main characteristics of industry ARS programs and how these programs contribute to new drug development. Industry ARS programs are generally performed to comply with requirements from regulatory agencies responsible for commercial approval of antimicrobial agents, such as the US Food and Drug Administration, European Medicines Agency, and others. In contrast to public health ARS programs, which typically collect health care and diverse clinical data, industry ARS programs frequently collect the pathogens and perform the testing in a central laboratory setting. Global ARS programs with centralized testing play an important role in new antibacterial and antifungal drug development by providing information on the emergence and dissemination of resistant organisms, clones, and resistance determinants. Organisms collected by large ARS programs are extremely valuable to evaluate the potential of new agents and to calibrate susceptibility tests once a drug is approved for clinical use. These programs also can provide early evaluations of spectrum of activity and postmarketing trends required by regulatory agencies, and the programs may help drug companies to select appropriate dosing regimens and the appropriate geographic regions in which to perform clinical trials. Furthermore, these surveillance programs provide useful information on the potency and spectrum of new antimicrobial agents against indications and organisms in which clinicians have little or no experience. In summary, large ARS programs, such as the SENTRY Antimicrobial Surveillance Program, contribute key data for new drug development.

journal_name

Open Forum Infect Dis

journal_title

Open forum infectious diseases

authors

Sader HS,Rhomberg PR,Fuhrmeister AS,Mendes RE,Flamm RK,Jones RN

doi

10.1093/ofid/ofy345

subject

Has Abstract

pub_date

2019-03-15 00:00:00

pages

S5-S13

issue

Suppl 1

issn

2328-8957

pii

ofy345

journal_volume

pub_type

杂志文章

在线工具

Antimicrobial Resistance Surveillance and New Drug Development.